These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 23075542

  • 21. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
    Chica-Guzmán MV, Morillo-Guerrero R, Carrón-Herrero A, González-de-Olano D, Almonacid-Sánchez C.
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
    [No Abstract] [Full Text] [Related]

  • 22. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE, Figliomeni M, Spector S.
    Allergy Asthma Proc; 2012 Aug; 33(5):377-85. PubMed ID: 23026179
    [Abstract] [Full Text] [Related]

  • 23. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [Abstract] [Full Text] [Related]

  • 24. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
    Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
    [No Abstract] [Full Text] [Related]

  • 25. Omalizumab in asthma: an update on recent developments.
    Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S.
    J Allergy Clin Immunol Pract; 2014 Nov; 2(5):525-36.e1. PubMed ID: 25213045
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
    Owens G, Petrov A.
    Curr Drug Saf; 2011 Nov 01; 6(5):339-42. PubMed ID: 22424542
    [Abstract] [Full Text] [Related]

  • 28. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May 03; 154(9):I28. PubMed ID: 21536934
    [No Abstract] [Full Text] [Related]

  • 29. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C, Spanish Registry.
    J Asthma; 2012 May 03; 49(4):416-22. PubMed ID: 22443408
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety of omalizumab in asthma.
    Tan RA, Corren J.
    Expert Opin Drug Saf; 2011 May 03; 10(3):463-71. PubMed ID: 21401438
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.
    Yalcin AD, Bisgin A.
    Med Sci Monit; 2012 Aug 03; 18(8):LE9-10. PubMed ID: 22847211
    [No Abstract] [Full Text] [Related]

  • 34. Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit.
    Cazzola M, Segreti A.
    Drugs; 2014 Apr 03; 74(5):535-7. PubMed ID: 24691708
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
    Di Stefano F, Cinti B, Antonicelli L.
    Eur Ann Allergy Clin Immunol; 2014 Jan 03; 46(1):56-9. PubMed ID: 24702879
    [Abstract] [Full Text] [Related]

  • 37. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.
    Curr Med Res Opin; 2011 Nov 03; 27(11):2223-8. PubMed ID: 21933100
    [Abstract] [Full Text] [Related]

  • 38. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J, Figliomeni M, Kianifard F, Meng X.
    J Asthma; 2012 Mar 03; 49(2):144-52. PubMed ID: 22277052
    [Abstract] [Full Text] [Related]

  • 39. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
    Asai N, Ohkuni Y, Komatsu A, Matsunuma R, Nakashima K, Kaneko N.
    J Bras Pneumol; 2011 Mar 03; 37(4):567-70. PubMed ID: 21881749
    [No Abstract] [Full Text] [Related]

  • 40. [Churg-Strauss syndrome under omalizumab treatment: a rare visceral manifestation].
    Szwarc D, Veillon F, Moser T, Averous G, De Blay F, Riehm S.
    J Radiol; 2009 Nov 03; 90(11 Pt 1):1737-9. PubMed ID: 19953062
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.